Janet Mokhnatkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janet Mokhnatkin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aleck Cervantes
Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA
3 shared publications - Alison Schwartz Levine
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3 shared publications - Benjamin L. Ebert
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3 shared publications - Bita Nehoray
City of Hope Cancer Center, Duarte, California
3 shared publications - Christopher Ian Amos
Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA
3 shared publications - Danielle Castillo
City of Hope, Duarte, CA
3 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Background:Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management.Methods:Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories.Results:Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases.Conclusions:We demonstrated an effective approach and tools for discerning germline TP53 status.Impact:Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Background:Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management.Methods:Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories.Results:Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases.Conclusions:We demonstrated an effective approach and tools for discerning germline TP53 status.Impact:Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Supplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Supplementary Figure from Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
- Open Access
- 1 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 649
Understanding the relationship between body image and emotional distress among men and women with cancer
Purpose: This study addresses key gaps in knowledge regarding two components of body image that impact the emotional well-being of cancer patients: physical appearance and body function. The study examines the interrelationship of anxiety and gender in endorsement of distress related to body function and physical appearance. Methods: A retrospective study was conducted involving 1563 patients treated for cancer at City of Hope between 2009 and 2017. Patients completed a biopsychosocial problem-related distress touch-screen instrument before treatment as part of their routine clinical care. Relationships between body image constructs (physical appearance, body function), anxiety, and gender were examined using mixed models. Models controlled demographic (age, marital status, household income, education, and survey language) and clinical variables (cancer type, disease stage). Results: An association between anxiety and gender (p < 0.001) was found and was associated with body image distress. With higher levels of anxiety, women were significantly more distressed than men regarding physical appearance (F = 6.94, p = 0.009), while men were significantly more distressed than women regarding body function (F = 4.05, p = 0.044). Conclusion: Distress regarding body image is an important factor to consider in patients with cancer. Understanding the impact of anxiety and gender upon physical appearance distress and body function distress can inform individualized medical and psychosocial care.
- 1 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 649
Open AccessUnderstanding the relationship between body image and emotional distress among men and women with cancer
Purpose: This study addresses key gaps in knowledge regarding two components of body image that impact the emotional well-being of cancer patients: physical appearance and body function. The study examines the interrelationship of anxiety and gender in endorsement of distress related to body function and physical appearance. Methods: A retrospective study was conducted involving 1563 patients treated for cancer at City of Hope between 2009 and 2017. Patients completed a biopsychosocial problem-related distress touch-screen instrument before treatment as part of their routine clinical care. Relationships between body image constructs (physical appearance, body function), anxiety, and gender were examined using mixed models. Models controlled demographic (age, marital status, household income, education, and survey language) and clinical variables (cancer type, disease stage). Results: An association between anxiety and gender (p < 0.001) was found and was associated with body image distress. With higher levels of anxiety, women were significantly more distressed than men regarding physical appearance (F = 6.94, p = 0.009), while men were significantly more distressed than women regarding body function (F = 4.05, p = 0.044). Conclusion: Distress regarding body image is an important factor to consider in patients with cancer. Understanding the impact of anxiety and gender upon physical appearance distress and body function distress can inform individualized medical and psychosocial care.
- 1 July 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (7) , 484-492
Facilitators and Barriers to Older Adult Participation in Cancer Trials: A Qualitative Study Exploring Patient-Caregiver Dyad Congruence
PURPOSE: Family caregivers play an integral role in caring for older adults with cancer. Few studies have examined older adults with cancer and their family caregivers as a unit in a relationship or a dyad. Dyad congruence, or consistency in perspective, is relevant to numerous aspects of living with cancer, including the decision to enroll in a cancer clinical trial. METHODS: Semistructured interviews of 32 older women (age ≥ 70 years) with breast cancer and their family caregivers (16 dyads) were conducted at both academic and community settings from December 2019 to March 2021 to explore perceived facilitators and barriers to cancer trials. Dyad congruence was defined as aligned (matching) perspectives, and incongruence was defined as misaligned (nonmatching) perspectives. RESULTS: Five (31%) of 16 patients were age ≥80 years, 11 (69%) had nonmetastatic breast cancer, and 14 (88%) were treated in an academic setting. Six (38%) of 16 caregivers were in the 50-59 age group, 10 (63%) were female, and seven (44%) were daughters. Dyad congruence centered on the clinical benefit of trials and physician recommendation. However, compared with caregivers, patients were more motivated to contribute to science. Patients and caregivers also differed on the perceived extent to which the caregiver influenced enrollment. CONCLUSION: Older patients with cancer and their caregivers generally agree about the facilitators and barriers to cancer trial enrollment, but some perceptions are misaligned. Further research is needed to understand whether misaligned perspectives between patients and caregivers influence clinical trial participation of older adults with cancer.
- 1 July 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (7) , 484-492
Facilitators and Barriers to Older Adult Participation in Cancer Trials: A Qualitative Study Exploring Patient-Caregiver Dyad Congruence
PURPOSE: Family caregivers play an integral role in caring for older adults with cancer. Few studies have examined older adults with cancer and their family caregivers as a unit in a relationship or a dyad. Dyad congruence, or consistency in perspective, is relevant to numerous aspects of living with cancer, including the decision to enroll in a cancer clinical trial. METHODS: Semistructured interviews of 32 older women (age ≥ 70 years) with breast cancer and their family caregivers (16 dyads) were conducted at both academic and community settings from December 2019 to March 2021 to explore perceived facilitators and barriers to cancer trials. Dyad congruence was defined as aligned (matching) perspectives, and incongruence was defined as misaligned (nonmatching) perspectives. RESULTS: Five (31%) of 16 patients were age ≥80 years, 11 (69%) had nonmetastatic breast cancer, and 14 (88%) were treated in an academic setting. Six (38%) of 16 caregivers were in the 50-59 age group, 10 (63%) were female, and seven (44%) were daughters. Dyad congruence centered on the clinical benefit of trials and physician recommendation. However, compared with caregivers, patients were more motivated to contribute to science. Patients and caregivers also differed on the perceived extent to which the caregiver influenced enrollment. CONCLUSION: Older patients with cancer and their caregivers generally agree about the facilitators and barriers to cancer trial enrollment, but some perceptions are misaligned. Further research is needed to understand whether misaligned perspectives between patients and caregivers influence clinical trial participation of older adults with cancer.
- 2 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (8) , 1621-1629
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Background: Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management. Methods: Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories. Results: Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases. Conclusions: We demonstrated an effective approach and tools for discerning germline TP53 status. Impact: Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.
- 2 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (8) , 1621-1629
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Background: Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li–Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning ACE/CH from germline variants and postzygotic mosaicism (PZM) is critically needed for risk assessment and management. Methods: Participants in the Li-Fraumeni & TP53 Understanding & Progress (LiFT UP) study with a TP53 PV were eligible. Demographics, personal/family cancer history, and clinical laboratory test reports were obtained. DNA from multiple tissues was analyzed using a custom QIAseq assay (ACE panel) that included TP53 and other CH-associated genes; the ACE panel and eyebrow follicles were assessed in a workflow to discern TP53 PV clinical categories. Results: Among 134 participants there was a significant difference for the age at diagnosis (P < 0.001), component cancers (P = 0.007), and clinical testing criteria (P < 0.001), comparing germline with PZM or ACE. ACE panel analysis of DNA from 55 sets of eyebrow follicles (mean 1.4 ug) and 36 formalin-fixed, paraffin imbedded tissues demonstrated low variance (SE, 3%; P = 0.993) for TP53 variant allele fraction, with no significant difference (P = 0.965) between tissue types, and detected CH gene PVs. Of 55 multi-tissue cases, germline status was confirmed for 20, PZM in seven, ACE for 25, and three were indeterminate. Additional CH variants were detected in six ACE and two germline cases. Conclusions: We demonstrated an effective approach and tools for discerning germline TP53 status. Impact: Discernment of PZM and TP53-driven CH increases diagnostic accuracy and enables risk-appropriate care.